Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

IgM multiple myeloma: pathologic evaluation of a rare entity.

King RL, Howard MT, Hodnefield JM, Morice WG.

Am J Clin Pathol. 2013 Oct;140(4):519-24. doi: 10.1309/AJCP0N7IELYUNJGZ.

PMID:
24045549
2.

IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).

Feyler S, O'Connor SJ, Rawstron AC, Subash C, Ross FM, Pratt G, Drayson MT, Ashcroft J, Cook G, Owen RG.

Br J Haematol. 2008 Mar;140(5):547-51. doi: 10.1111/j.1365-2141.2007.06969.x.

PMID:
18275432
3.

Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.

Alley CL, Wang E, Dunphy CH, Gong JZ, Lu CM, Boswell EL, Burchette J, Lagoo AS.

Arch Pathol Lab Med. 2013 Apr;137(4):503-17. doi: 10.5858/arpa.2011-0696-OA. Review.

PMID:
23544940
4.

The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.

Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ.

Am J Clin Pathol. 2000 Jun;113(6):831-7.

PMID:
10874884
5.

Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia.

Miura K, Iida S, Hanamura I, Kato M, Banno S, Ishida T, Kusumoto S, Takeuchi G, Miwa H, Nitta M, Inagaki H, Eimoto T, Nomura K, Taniwaki M, Ueda R.

Cancer Sci. 2003 Apr;94(4):350-4.

6.

A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.

Yufu Y, Goto T, Choi I, Uike N, Kozuru M, Ohshima K, Taniguchi T, Motokura T, Yatabe Y, Nakamura S.

Cancer. 1999 Apr 15;85(8):1750-7.

PMID:
10223569
7.

CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features.

Schmidt-Hieber M, Pérez-Andrés M, Paiva B, Flores-Montero J, Perez JJ, Gutierrez NC, Vidriales MB, Matarraz S, San Miguel JF, Orfao A.

Haematologica. 2011 Feb;96(2):328-32. doi: 10.3324/haematol.2010.031872. Epub 2010 Oct 22.

8.

Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.

Cook JR, Hsi ED, Worley S, Tubbs RR, Hussein M.

Am J Clin Pathol. 2006 Apr;125(4):615-24.

PMID:
16627271
9.

Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.

Wilson CS, Butch AW, Lai R, Medeiros LJ, Sawyer JR, Barlogie B, McCourty A, Kelly K, Brynes RK.

Br J Haematol. 2001 Mar;112(3):776-82.

PMID:
11260083
10.

Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

Pruneri G, Fabris S, Baldini L, Carboni N, Zagano S, Colombi MA, Ciceri G, Lombardi L, Rocchi M, Buffa R, Maiolo AT, Neri A.

Am J Pathol. 2000 May;156(5):1505-13.

11.

MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.

Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED.

Am J Clin Pathol. 2013 Sep;140(3):387-94. doi: 10.1309/AJCP10ZCLFZGYZIP.

PMID:
23955458
12.

Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.

Katayama Y, Sakai A, Okikawa Y, Oue N, Asaoku H, Sasaki A, Imanaka F, Tsujimoto T, Takimoto Y, Masuda R, Nakaju N, Otsuki T, Yasui W, Kimura A.

Int J Oncol. 2004 Sep;25(3):579-95.

PMID:
15289859
13.

CD20-negative low-grade B cell lymphoma showing immunophenotypic and genotypic features resembling plasma cell myeloma.

Tabata R, Yasumizu R, Tabata C, Kojima M.

Pathol Res Pract. 2013 Jul;209(7):459-62. doi: 10.1016/j.prp.2013.04.007. Epub 2013 Apr 30.

PMID:
23707547
14.

Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.

Krämer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, Goldschmidt H, Hehlmann R.

Leukemia. 2002 Sep;16(9):1844-51.

15.

Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.

Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, Yamaguchi M, Tamaru J, Uike N, Hashimoto Y, Morishima Y, Suchi T, Seto M, Nakamura S.

Blood. 2000 Apr 1;95(7):2253-61.

16.

t(1;14) and t(11;18) in the differential diagnosis of Waldenström's macroglobulinemia.

Ye H, Chuang SS, Dogan A, Isaacson PG, Du MQ.

Mod Pathol. 2004 Sep;17(9):1150-4.

17.

Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens.

Athanasiou E, Kaloutsi V, Kotoula V, Hytiroglou P, Kostopoulos I, Zervas C, Kalogiannidis P, Fassas A, Christakis JI, Papadimitriou CS.

Am J Clin Pathol. 2001 Oct;116(4):535-42.

PMID:
11601138
18.

The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.

Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M.

Blood. 1997 Jul 15;90(2):526-34.

19.

IgM myeloma: case report with immunophenotypic profile.

Haghighi B, Yanagihara R, Cornbleet PJ.

Am J Hematol. 1998 Dec;59(4):302-8.

20.

[Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].

Matsuda I, Mori Y, Nakagawa Y, Sawanobori M, Uemura N, Suzuki K.

Rinsho Ketsueki. 2005 Dec;46(12):1293-7. Japanese.

PMID:
16447802

Supplemental Content

Support Center